SCHEMBL287345

SCHEMBL287345

N#CC(OC(N)=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP1A2 P05177 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44
ALOX5 P09917 1/20 0.41
EPHX1 P07099 1/20 0.41
TRPA1 O75762 1/20 0.39
ALDH1A1 P00352 4/20 0.39
TDP1 Q9NUW8 2/20 0.39
CYP2C19 P33261 1/20 0.39
LMNA P02545 2/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C1 Q04828 1/20 0.38
SRC P12931 1/20 0.38
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18978225 0.86 SRC (0.41) SMN1; SMN2NPSR1CYP2D6CYP1A2PKM
SCHEMBL5932426 0.83 TSHR (0.45) SMN1; SMN2NPSR1CYP2D6TSHRTRPA1
SCHEMBL2835326 0.81 ALDH1A1 (0.50) SMN1; SMN2NPSR1CYP2D6TSHRTRPA1
Carfimate SCHEMBL1648782 0.81 CYP2D6 (0.44) SMN1; SMN2NPSR1CYP2D6CYP1A2PKM
SCHEMBL5932510 0.81 TSHR (0.44) SMN1; SMN2NPSR1CYP2D6TSHRTRPA1
SCHEMBL7699172 0.81 ALDH1A1 (0.50) SMN1; SMN2NPSR1CYP2D6TSHRTRPA1
SCHEMBL15453000 0.81 TSHR (0.44) SMN1; SMN2NPSR1CYP2D6TSHRTRPA1
SCHEMBL28174202 0.81 CTSD (0.44) SMN1; SMN2NPSR1CYP2D6CYP1A2PKM
SCHEMBL4801484 0.80 TSHR (0.42) SMN1; SMN2NPSR1CYP2D6CYP1A2PKM
SCHEMBL8964823 0.80 TSHR (0.52) SMN1; SMN2NPSR1CYP2D6CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis THE GENERAL HOSPITAL CORPORATION (US) 2022-02-08 US claimed
US-12486289-B2 Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof THE BROAD INSTITUTE, INC. (US) 2025-12-02 US disclosed
US-12377037-B2 Cleavable comonomer strategy for accelerating removal of gel nail polish MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-08-05 US disclosed
WO-2025151874-A1 INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-07-17 WO disclosed
US-20250144227-A1 C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2025-05-08 US disclosed
US-20240423894-A1 CLEAVABLE COMONOMER STRATEGY FOR ACCELERATING REMOVAL OF GEL NAIL POLISH MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2024-12-26 US disclosed
US-12116364-B2 Heteroaryl compounds and uses thereof APRINOIA THERAPEUTICS INC. (CN) 2024-10-15 US disclosed
US-12083186-B2 Methods for assembling scavenging particles NANOTICS, LLC (US) 2024-09-10 US disclosed
US-20240269319-A1 METHODS FOR ASSEMBLING SCAVENGING PARTICLES NANOTICS, LLC 2024-08-15 US disclosed
US-20240228475-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE CELGENE CORPORATION 2024-07-11 US disclosed
WO-2008028057-A2 SHIKIMIC ACID-DERIVED COMPOUNDS FOR INHIBITION AND DETECTION OF AURORA A-ASSOCIATED TUMORS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2008-03-06 WO disclosed
EP-1863800-A2 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF The President and Fellows of Harvard College (US) 2007-12-12 EP disclosed
WO-2007008226-A9 PALLADIUM-CATALYZED CARBON-CARBON BOND FORMING REACTIONS HARVARD COLLEGE (US) 2007-05-24 WO disclosed
WO-2007056188-A1 SYNTHESIS OF INHIBITORS OF FTSZ PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-05-18 WO disclosed
EP-1753713-A2 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF The President and Fellows of Harvard College (US) 2007-02-21 EP disclosed
WO-2007013965-A2 SYNTHESIS OF SCABRONINES AND ANALOGUES THEREOF SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 2007-02-01 WO disclosed
WO-2006102097-A2 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2006-09-28 WO disclosed
WO-2005112945-A2 SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2005-12-01 WO disclosed
CN-1079679-C Cascade polymer complexes, method for the production thereof and pharmaceutical agents containing said complexes SCHERING AG (DE) 2002-02-27 CN disclosed
CN-1189779-A Cascade polymer complexes, method for the production thereof and pharmaceutical agents containing said complexes SCHERING AG (DE) 1998-08-05 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12377037-B2 Cleavable comonomer strategy for accelerating removal of gel nail polish PRKDC, POLR1C, PIK3C3 SMN1; SMN2 4325/4885NPSR1 4275/4885CYP2D6 1514/4885
US-20240423894-A1 CLEAVABLE COMONOMER STRATEGY FOR ACCELERATING REMOVAL OF GEL NAIL POLISH PRKDC, POLR1C, NACA SMN1; SMN2 4034/4885NPSR1 4117/4885CYP2D6 1994/4885
US-20250144227-A1 C-16 MODIFIED TRIOXACARCINS, ANTIBODY DRUG CONJUGATES, AND USES THEREOF UGT2B17, ABCB4, IL17A SMN1; SMN2 3215/4885NPSR1 3722/4885CYP2D6 208/4885
US-12486289-B2 Tricyclic compounds as glycogen synthase kinase 3 (GSK3) inhibitors and uses thereof GSK3A, GSK3B, PYGB SMN1; SMN2 1825/4885NPSR1 3905/4885CYP2D6 673/4885
US-20240228475-A1 PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE AQP1, AQP3, ADH1C SMN1; SMN2 738/4885NPSR1 1614/4885CYP2D6 134/4885
US-12116364-B2 Heteroaryl compounds and uses thereof MAPT, APP, SLCO1B3 SMN1; SMN2 2412/4885NPSR1 806/4885CYP2D6 365/4885
US-11241435-B2 Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis SOST, SIK2, SIK1 SMN1; SMN2 3838/4885NPSR1 865/4885CYP2D6 4818/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.